Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have recently been diagnosed with lymphoblastic lymphoma for the first time
- Children and young people under 18 years of age
- People who are being treated at a hospital or centre that is part of this trial
- People (aged over 14, or as required by local rules) and their parents or guardians who are willing to give written agreement to take part and allow their information to be used in the trial
- People and their doctors who are willing to provide tissue samples (such as slides or frozen samples) for specialised testing, if those samples are available after standard diagnostic tests have already been done
Who may not be able to join:
- People whose lymphoblastic lymphoma developed as a result of a previous cancer or cancer treatment
- People with certain serious non-cancer medical, mental health, or social conditions that are not compatible with the trial treatment, including:
- A history of organ transplant
- A severely weakened immune system
- A nerve condition called Charcot-Marie-Tooth syndrome (a type of inherited nerve disorder)
- Serious ongoing infections such as HIV, chickenpox/shingles (VZV), or tuberculosis
- Urinary tract infection, bladder inflammation, blockage of urinary flow, or severely reduced kidney function
- Severely reduced liver function
- Heart muscle weakness or serious irregular heartbeat
- Mouth ulcers or known active stomach or intestinal ulcers
- A known allergy to any of the trial medications or their ingredients
- People who have taken high-dose steroid medication (at or above a certain dose level) for more than two weeks in the month before diagnosis
- People who have received a live vaccine within 2 weeks before starting the trial treatment
- People who have already started treatment under a different medical protocol, or who have previously received chemotherapy drugs
- People who are already taking part in another clinical trial that would interfere with this one (note: participation in the NHL-BFM Registry 2012 or certain supportive care trials, such as those studying anti-nausea medication, antibiotics, or psychosocial support, may still be permitted — confirm with the trial site)
- People who are pregnant or breastfeeding
- Sexually active young people who are not willing to use a highly effective form of contraception for up to 12 months after chemotherapy treatment ends
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Birgit Burkhardt, Prof. Dr. Dr., University Hospital Muenster, Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie
Phone: +49 251 83 55696
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cumulative incidence of relapse with involvement of the CNS (CNS-relapse, pCICR); Estimated probability of event-free survival (pEFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.